Literature DB >> 23419434

Impact of ABO-mismatch on risk of GVHD after umbilical cord blood transplantation.

R Romee1, D J Weisdorf, C Brunstein, J E Wagner, Q Cao, B R Blazar, N S Majhail, G M Vercellotti, J S Miller, M Arora.   

Abstract

Recent advances in allogeneic hematopoietic cell transplant (allo-HCT) have led to an increasing use of alternative donors, including banked umbilical cord blood (UCB). Despite these advances, acute GVHD (aGVHD) and chronic GVHD (cGVHD) continue to be the leading causes of early and late transplant-related mortality. ABO-mismatch has been frequently reported as a risk factor for GVHD, however, data in the UCB recipients are limited. We hypothesized that as the lymphocytes in the cord blood are thought to be naive, they will therefore be less likely to mediate GVHD. Therefore, we analyzed the impact of ABO-mismatch on aGVHD and cGVHD in recipients of single and double UCB-HCT. In both univariate and multivariate analyses, presence of ABO-mismatch did not have an impact on aGVHD or cGVHD. Whereas ABO-compatible donors are preferred in recipients of URD-HCT, ABO compatibility generally need not be considered in recipients of UCB-HCT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23419434      PMCID: PMC3740145          DOI: 10.1038/bmt.2013.8

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  19 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

Review 2.  Immunohematologic complications of bone marrow transplantation.

Authors:  T R Klumpp
Journal:  Bone Marrow Transplant       Date:  1991-09       Impact factor: 5.483

3.  ABO blood group barrier in allogeneic bone marrow transplantation revisited.

Authors:  Jörg D Seebach; Georg Stussi; Jakob R Passweg; Fausto R Loberiza; James L Gajewski; Armand Keating; Martin Goerner; Philip A Rowlings; Pierre Tiberghien; Gerald J Elfenbein; Robert Peter Gale; Jon J van Rood; Vijay Reddy; Eliane Gluckman; Brian J Bolwell; Thomas R Klumpp; Mary M Horowitz; Olle Ringdén; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

4.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

Authors:  Alexandra H Filipovich; Daniel Weisdorf; Steven Pavletic; Gerard Socie; John R Wingard; Stephanie J Lee; Paul Martin; Jason Chien; Donna Przepiorka; Daniel Couriel; Edward W Cowen; Patricia Dinndorf; Ann Farrell; Robert Hartzman; Jean Henslee-Downey; David Jacobsohn; George McDonald; Barbara Mittleman; J Douglas Rizzo; Michael Robinson; Mark Schubert; Kirk Schultz; Howard Shulman; Maria Turner; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

5.  ABO glycosyltransferases as potential source of minor histocompatibility antigens in allogeneic peripheral blood progenitor cell transplantation.

Authors:  Britta Eiz-Vesper; Axel Seltsam; Rainer Blasczyk
Journal:  Transfusion       Date:  2005-06       Impact factor: 3.157

6.  Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect.

Authors:  M Mielcarek; W Leisenring; B Torok-Storb; R Storb
Journal:  Blood       Date:  2000-08-01       Impact factor: 22.113

7.  ABO incompatibility between donor and recipient and clinical outcomes in allogeneic stem cell transplantation.

Authors:  James Goldman; Jane Liesveld; Diane Nichols; Joanna Heal; Neil Blumberg
Journal:  Leuk Res       Date:  2003-06       Impact factor: 3.156

8.  Factors with an impact on chimerism development and long-term survival after umbilical cord blood transplantation.

Authors:  Sofia Berglund; Katarina Le Blanc; Mats Remberger; Jens Gertow; Mehmet Uzunel; Petter Svenberg; Jacek Winiarski; Per Ljungman; Olle Ringdén; Michael Uhlin; Jonas Mattsson
Journal:  Transplantation       Date:  2012-11-27       Impact factor: 4.939

9.  Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation.

Authors:  G Stussi; J Muntwyler; J R Passweg; L Seebach; U Schanz; J Gmür; A Gratwohl; J D Seebach
Journal:  Bone Marrow Transplant       Date:  2002-07       Impact factor: 5.483

Review 10.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

View more
  4 in total

1.  Optimizing selection of double cord blood units for transplantation of adult patients with malignant diseases.

Authors:  Giancarlo Fatobene; Fernanda Volt; Frederico Moreira; Lívia Mariano; Patrice Chevallier; Sabine Furst; Hélène Labussière-Wallet; Régis Peffault de la Tour; Eric Deconinck; Thomas Cluzeau; Nigel Russell; Dimitrios Karakasis; Edouard Forcade; Annalisa Ruggeri; Eliane Gluckman; Vanderson Rocha
Journal:  Blood Adv       Date:  2020-12-22

2.  Impact of Graft-Recipient ABO Compatibility on Outcomes after Umbilical Cord Blood Transplant for Nonmalignant Disease.

Authors:  Matthew R Kudek; Ryan Shanley; Nicole D Zantek; David H McKenna; Angela R Smith; Weston P Miller
Journal:  Biol Blood Marrow Transplant       Date:  2016-08-02       Impact factor: 5.742

3.  Impact of ABO blood group mismatch in alemtuzumab-based reduced-intensity conditioned haematopoietic SCT.

Authors:  C K Brierley; T J Littlewood; A J Peniket; R Gregg; J Ward; A Clark; A Parker; R Malladi; P Medd
Journal:  Bone Marrow Transplant       Date:  2015-04-13       Impact factor: 5.483

4.  Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

Authors:  Y Arai; J Kanda; H Nakasone; T Kondo; N Uchida; T Fukuda; K Ohashi; K Kaida; K Iwato; T Eto; Y Kanda; H Nakamae; T Nagamura-Inoue; Y Morishima; M Hirokawa; Y Atsuta; M Murata
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.